AesMed Participates in KALDAT 2025 Fall Scientific Meeting, Showcasing Advanced Cytokine-Based Alopecia Treatment

AesMed Participates in KALDAT 2025 Fall Scientific Meeting, Showcasing Advanced Cytokine-Based Alopecia Treatment

AesMed announced its successful participation as an exhibitor at KALDAT 2025 – The 51st Fall Scientific Meeting of the Korean Academy of Laser, Dermatology and Trichology, held on December 14, 2025, in Seoul.
The annual scientific meeting brought together leading dermatologists, hair-loss specialists, and medical professionals to discuss the latest research, technologies, and clinical approaches in the diagnosis and treatment of alopecia.

Introducing CytoMesopecia – Cytokines Mesotherapy for Alopecia
At the exhibition booth, AesMed introduced CytoMesopecia – Cytokines Mesotherapy for Alopecia, a differentiated treatment concept that integrates cytokine science with mesotherapy-based scalp delivery.

CytoMesopecia reflects AesMed’s scientific approach to alopecia treatment, focusing on:
•    Optimization of the follicular microenvironment
•    Regulation of cytokine signaling related to hair growth cycles
•    Support for anagen phase maintenance and follicular vitality
•    A biologically driven strategy beyond conventional drug-centered therapies

The concept attracted strong interest from attending clinicians seeking next-generation, regenerative approaches to hair loss management.

Active Engagement With the Academic Hair Loss Community
Throughout the conference, AesMed engaged in meaningful discussions with medical professionals on emerging trends in regenerative medicine, cytokine science, and mesotherapy-based treatments for alopecia.

By participating in KALDAT 2025, AesMed reinforced its commitment to staying closely connected with academic research and clinical practice, ensuring that its technologies align with real-world medical needs and evolving scientific standards.

AesMed’s Ongoing Commitment to Innovation
AesMed continues to focus on the development of science-based, clinically applicable solutions for hair loss treatment. Through ongoing research, professional education, and collaboration with the medical community, the company aims to further advance CytoMesopecia – Cytokines Mesotherapy for Alopecia as a meaningful framework in modern alopecia care.

Looking Forward
Following its participation in KALDAT 2025, AesMed plans to expand academic collaboration and professional engagement both domestically and internationally, contributing to the future of evidence-based and biologically driven hair loss treatment.

► Learn more about AesMed: www.aesmed.co.kr